The Chemours Company repriced its tranche B-3 U.S. dollar-denominated term loan under its senior secured term loan facility due in August 2028. The repricing reduces the applicable margin in respect of the company’s $1.07 billion senior secured U.S. dollar-denominated term loan facility from, at the election of the company, adjusted term SOFR + 3.50% to adjusted term SOFR + 3.00%, or adjusted base rate plus 2.50% to adjusted base rate plus 2.00%. There are no changes to the maturity of the term loan B-3 US$ facility following this repricing, and all other terms are substantially unchanged.
Forward for Specialty Finance
